BioSpace News Archive

BD, a leading global medical technology company, announced Greg Rodetis, currently BD senior vice president and treasurer will also add head of investor relations to his responsibilities, effective immediately.

TeselaGen Biotechnology Inc., the software company providing an all-in-one platform for seamless, scalable biotech R&D, announces the acquisition of two cutting-edge patents that advance AI-driven optimization of biological phenotypes.

Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced findings from a retrospective database analysis of adjudicated claims data that examined the impact of access barriers for commercially-insured adults prescribed Xifaxan® for reduction in risk of overt hepatic encephalopathy recurrence in adults.

GE HealthCare, a leader in precision care innovation, will announce its third quarter 2023 financial results before the market opens on Tuesday, October 31, 2023.

Kineta, Inc. (Nasdaq: KA) announced today that the first patient has been dosed in Part B of its Phase 1/2 VISTA-101 clinical trial that will evaluate the safety and tolerability of the company’s VISTA blocking immunotherapy, KVA12123, in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors.

DarioHealth Corp. announced new research presented by Sanofi U.S. at the Academy of Managed Care Pharmacy’s 2023 annual conference Nexus, demonstrating a 36% reduction in 30-day hospital readmissions for Dario users compared to non-users living with type 2 diabetes.

Champions Oncology, Inc., a global preclinical and clinical research services provider that offers end-to-end oncology solutions, has appointed Brady Davis as President to continue to develop new strategic initiatives to drive accelerated growth.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 third quarter on Thursday, November 9, 2023 before the open of the U.S. financial markets

Phoenix Children’s, one of the nation’s fastest-growing pediatric health systems, continues to strengthen its focus on pediatric research with the hire of Tanya Kalin, MD, PhD, a renowned scientist focused on pioneering effective treatments for pediatric cancers with fewer negative side effects for children.

NS Pharma, Inc. announced today the publication of preclinical data on NS-089/NCNP-02 (brogidirsen), an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy, in the journal Molecular Therapy Nucleic Acids.